Hanne L. Gulseth

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis

Kåre I. Birkeland, Marit E. Jørgensen, Bendix Carstensen et al. · The Lancet Diabetes & Endocrinology · 2017 · 371 citations

Medicine, Internal Medicine, Pharmacotherapy +17

Effects of dietary fat modification on insulin sensitivity and on other risk factors of the metabolic syndrome—LIPGENE: a European randomized dietary intervention study

Audrey Tierney, Jolene McMonagle, D. I. Shaw et al. · International Journal of Obesity · 2010 · 234 citations

Medicine, Nutrition, Nutritional Sciences +16

Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes ( <scp>CVD‐REAL Nordic</scp> ) when compared with dipeptidyl peptidase‐4 inhibitor therapy: <scp>A</scp> multinational observational study

Frederik Persson, Thomas Nyström, Marit E. Jørgensen et al. · Diabetes Obesity and Metabolism · 2017 · 217 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial

Dag Hofsø, Farhat Fatima, Heidi Borgeraas et al. · The Lancet Diabetes & Endocrinology · 2019 · 203 citations · Full text

Medicine, Internal Medicine, Surgery +11

Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial

Matthias von Herrath, Stephen C. Bain, Bruce W. Bode et al. · The Lancet Diabetes & Endocrinology · 2021 · 178 citations · Full text

Medicine, Endocrinology, Immunology +16